Skip to main content
. 2017 Aug 28;8(44):76558–76573. doi: 10.18632/oncotarget.20576

Figure 4. FXR deficiency increases rosiglitazone-induced bone loss in vivo.

Figure 4

Male 12-week-old FXR+/+ and FXR−/− mice were orally administered daily with rosiglitazone (10 mg/kg) for 2 months, and mouse femurs were collected. (A) Femurs of FXR+/+ or FXR−/− mice from each group. (B) BMD (g/cm2) of femurs from FXR+/+ and FXR−/− mice was analyzed by DXA. (C–G) Various bone parameters were analyzed by micro-CT. BV/TV (%) (C), Tb.Th (mm) (D), Tb.N (/mm) (E), Tb.Sp (mm) (F), SMI (G). (H) Two-dimensional micro-CT images of the distal metaphysis of the femurs. *p < 0.05, **p < 0.01. BMD, bone mineral density; BV/TV, bone volume per tissue volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; SMI, structural model index.